Annual Total Liabilities
$256.48 M
+$19.10 M+8.05%
31 December 2023
Summary:
Heron Therapeutics annual total liabilities is currently $256.48 million, with the most recent change of +$19.10 million (+8.05%) on 31 December 2023. During the last 3 years, it has risen by +$139.41 million (+119.09%). HRTX annual total liabilities is now at all-time high.HRTX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$260.78 M
+$4.71 M+1.84%
30 September 2024
Summary:
Heron Therapeutics quarterly total liabilities is currently $260.78 million, with the most recent change of +$4.71 million (+1.84%) on 30 September 2024. Over the past year, it has increased by +$3.80 million (+1.48%). HRTX quarterly total liabilities is now -1.85% below its all-time high of $265.70 million, reached on 30 June 2022.HRTX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HRTX Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +8.1% | +1.5% |
| 3 y3 years | +119.1% | +11.7% |
| 5 y5 years | +178.7% | +142.5% |
HRTX Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +119.1% | -1.9% | +14.3% |
| 5 y | 5 years | at high | +178.7% | -1.9% | +142.5% |
| alltime | all time | at high | >+9999.0% | -1.9% | >+9999.0% |
Heron Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $260.78 M(+1.8%) |
| June 2024 | - | $256.08 M(+1.8%) |
| Mar 2024 | - | $251.65 M(-1.9%) |
| Dec 2023 | $256.48 M(+8.0%) | $256.48 M(-0.2%) |
| Sept 2023 | - | $256.99 M(+6.9%) |
| June 2023 | - | $240.51 M(+3.5%) |
| Mar 2023 | - | $232.31 M(-2.1%) |
| Dec 2022 | $237.38 M(+4.1%) | $237.38 M(-4.9%) |
| Sept 2022 | - | $249.50 M(-6.1%) |
| June 2022 | - | $265.70 M(+6.4%) |
| Mar 2022 | - | $249.76 M(+9.5%) |
| Dec 2021 | $228.14 M(+94.9%) | $228.14 M(-2.3%) |
| Sept 2021 | - | $233.54 M(-4.3%) |
| June 2021 | - | $244.14 M(+112.8%) |
| Mar 2021 | - | $114.71 M(-2.0%) |
| Dec 2020 | $117.06 M(+7.5%) | $117.06 M(+3.7%) |
| Sept 2020 | - | $112.88 M(+3.9%) |
| June 2020 | - | $108.66 M(-4.2%) |
| Mar 2020 | - | $113.47 M(+4.2%) |
| Dec 2019 | $108.95 M(+18.4%) | $108.95 M(+1.3%) |
| Sept 2019 | - | $107.52 M(+1.1%) |
| June 2019 | - | $106.31 M(+2.2%) |
| Mar 2019 | - | $103.98 M(+13.0%) |
| Dec 2018 | $92.02 M(-10.8%) | $92.02 M(+43.6%) |
| Sept 2018 | - | $64.09 M(-18.5%) |
| June 2018 | - | $78.67 M(-13.7%) |
| Mar 2018 | - | $91.18 M(-11.6%) |
| Dec 2017 | $103.17 M(+16.3%) | $103.17 M(+32.0%) |
| Sept 2017 | - | $78.14 M(+6.6%) |
| June 2017 | - | $73.30 M(-16.1%) |
| Mar 2017 | - | $87.40 M(-1.5%) |
| Dec 2016 | $88.73 M(+349.6%) | $88.73 M(+9.6%) |
| Sept 2016 | - | $80.93 M(+190.2%) |
| June 2016 | - | $27.89 M(+45.5%) |
| Mar 2016 | - | $19.17 M(-2.9%) |
| Dec 2015 | $19.73 M(+44.9%) | $19.73 M(+20.0%) |
| Sept 2015 | - | $16.45 M(-0.8%) |
| June 2015 | - | $16.59 M(+42.7%) |
| Mar 2015 | - | $11.63 M(-14.6%) |
| Dec 2014 | $13.62 M(+94.8%) | $13.62 M(+20.8%) |
| Sept 2014 | - | $11.27 M(+4.5%) |
| June 2014 | - | $10.79 M(+46.2%) |
| Mar 2014 | - | $7.38 M(+5.6%) |
| Dec 2013 | $6.99 M(+68.3%) | $6.99 M(+27.2%) |
| Sept 2013 | - | $5.50 M(-42.7%) |
| June 2013 | - | $9.59 M(+26.3%) |
| Mar 2013 | - | $7.60 M(+82.9%) |
| Dec 2012 | $4.15 M(+12.5%) | $4.15 M(-2.1%) |
| Sept 2012 | - | $4.24 M(+36.2%) |
| June 2012 | - | $3.12 M(-7.3%) |
| Mar 2012 | - | $3.36 M(-9.0%) |
| Dec 2011 | $3.69 M(+131.5%) | $3.69 M(+41.8%) |
| Sept 2011 | - | $2.60 M(-19.4%) |
| June 2011 | - | $3.23 M(+86.8%) |
| Mar 2011 | - | $1.73 M(+8.4%) |
| Dec 2010 | $1.59 M(-26.0%) | $1.59 M(+2.4%) |
| Sept 2010 | - | $1.56 M(-45.3%) |
| June 2010 | - | $2.85 M(+28.8%) |
| Mar 2010 | - | $2.21 M(+2.6%) |
| Dec 2009 | $2.15 M(-48.7%) | $2.15 M(-15.7%) |
| Sept 2009 | - | $2.56 M(-25.2%) |
| June 2009 | - | $3.41 M(-9.3%) |
| Mar 2009 | - | $3.76 M(-10.4%) |
| Dec 2008 | $4.20 M(-43.8%) | $4.20 M(-37.9%) |
| Sept 2008 | - | $6.76 M(+8.3%) |
| June 2008 | - | $6.25 M(-7.1%) |
| Mar 2008 | - | $6.72 M(-10.0%) |
| Dec 2007 | $7.48 M(+44.0%) | $7.48 M(+64.0%) |
| Sept 2007 | - | $4.56 M(+0.1%) |
| June 2007 | - | $4.55 M(-3.8%) |
| Mar 2007 | - | $4.74 M(-8.8%) |
| Dec 2006 | $5.19 M | $5.19 M(+114.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2006 | - | $2.42 M(+5.2%) |
| June 2006 | - | $2.30 M(+3.7%) |
| Mar 2006 | - | $2.22 M(-19.8%) |
| Dec 2005 | $2.77 M(-3.3%) | $2.77 M(+10.3%) |
| Sept 2005 | - | $2.51 M(+3.2%) |
| June 2005 | - | $2.43 M(+24.2%) |
| Mar 2005 | - | $1.96 M(-31.6%) |
| Dec 2004 | $2.86 M(+51.2%) | $2.86 M(+27.0%) |
| Sept 2004 | - | $2.25 M(+22.9%) |
| June 2004 | - | $1.83 M(-27.2%) |
| Mar 2004 | - | $2.52 M(+33.1%) |
| Dec 2003 | $1.89 M(-18.5%) | $1.89 M(-10.0%) |
| Sept 2003 | - | $2.10 M(-8.6%) |
| June 2003 | - | $2.30 M(-10.3%) |
| Mar 2003 | - | $2.56 M(+10.4%) |
| Dec 2002 | $2.32 M(-46.4%) | $2.32 M(-28.9%) |
| Sept 2002 | - | $3.27 M(-13.5%) |
| June 2002 | - | $3.77 M(+5.3%) |
| Mar 2002 | - | $3.59 M(-17.3%) |
| Dec 2001 | $4.33 M(-25.7%) | $4.33 M(+8.6%) |
| Sept 2001 | - | $3.99 M(-16.4%) |
| June 2001 | - | $4.77 M(+0.1%) |
| Mar 2001 | - | $4.77 M(-18.3%) |
| Dec 2000 | $5.84 M(-19.6%) | $5.84 M(-8.8%) |
| Sept 2000 | - | $6.40 M(-4.4%) |
| June 2000 | - | $6.70 M(-33.3%) |
| Mar 2000 | - | $10.05 M(+38.4%) |
| Dec 1999 | $7.26 M(-48.5%) | $7.26 M(-45.0%) |
| Sept 1999 | - | $13.20 M(+63.0%) |
| June 1999 | - | $8.10 M(-17.3%) |
| Mar 1999 | - | $9.80 M(-30.5%) |
| Dec 1998 | $14.10 M(+0.7%) | $14.10 M(+34.3%) |
| Sept 1998 | - | $10.50 M(-11.0%) |
| June 1998 | - | $11.80 M(-6.3%) |
| Mar 1998 | - | $12.60 M(-10.0%) |
| Dec 1997 | $14.00 M(+4.5%) | $14.00 M(+0.7%) |
| Sept 1997 | - | $13.90 M(-0.7%) |
| June 1997 | - | $14.00 M(+0.7%) |
| Mar 1997 | - | $13.90 M(+3.7%) |
| Dec 1996 | $13.40 M(-25.1%) | $13.40 M(-15.7%) |
| Sept 1996 | - | $15.90 M(-0.6%) |
| June 1996 | - | $16.00 M(+0.6%) |
| Mar 1996 | - | $15.90 M(-11.2%) |
| Dec 1995 | $17.90 M(+53.0%) | $17.90 M(+2.9%) |
| Sept 1995 | - | $17.40 M(+16.8%) |
| June 1995 | - | $14.90 M(-3.2%) |
| Mar 1995 | - | $15.40 M(+31.6%) |
| Dec 1994 | $11.70 M(-15.8%) | $11.70 M(-9.3%) |
| Sept 1994 | - | $12.90 M(-18.9%) |
| June 1994 | - | $15.90 M(-7.6%) |
| Mar 1994 | - | $17.20 M(+23.7%) |
| Dec 1993 | $13.90 M(+71.6%) | $13.90 M(+12.1%) |
| Sept 1993 | - | $12.40 M(-21.5%) |
| June 1993 | - | $15.80 M(+100.0%) |
| Mar 1993 | - | $7.90 M(-2.5%) |
| Dec 1992 | $8.10 M(+26.6%) | $8.10 M(-1.2%) |
| Sept 1992 | - | $8.20 M(+34.4%) |
| June 1992 | - | $6.10 M(+17.3%) |
| Mar 1992 | - | $5.20 M(-18.8%) |
| Dec 1991 | $6.40 M(+20.8%) | $6.40 M(+25.5%) |
| Sept 1991 | - | $5.10 M(0.0%) |
| June 1991 | - | $5.10 M(+2.0%) |
| Mar 1991 | - | $5.00 M(-5.7%) |
| Dec 1990 | $5.30 M(+43.2%) | $5.30 M(+39.5%) |
| Sept 1990 | - | $3.80 M(0.0%) |
| June 1990 | - | $3.80 M(+2.7%) |
| Mar 1990 | - | $3.70 M(0.0%) |
| Dec 1989 | $3.70 M(+5.7%) | $3.70 M(0.0%) |
| Sept 1989 | - | $3.70 M(-2.6%) |
| June 1989 | - | $3.80 M(+8.6%) |
| Dec 1988 | $3.50 M(-7.9%) | $3.50 M(-7.9%) |
| Dec 1987 | $3.80 M | $3.80 M |
FAQ
- What is Heron Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Heron Therapeutics?
- What is Heron Therapeutics annual total liabilities year-on-year change?
- What is Heron Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Heron Therapeutics?
- What is Heron Therapeutics quarterly total liabilities year-on-year change?
What is Heron Therapeutics annual total liabilities?
The current annual total liabilities of HRTX is $256.48 M
What is the all time high annual total liabilities for Heron Therapeutics?
Heron Therapeutics all-time high annual total liabilities is $256.48 M
What is Heron Therapeutics annual total liabilities year-on-year change?
Over the past year, HRTX annual total liabilities has changed by +$19.10 M (+8.05%)
What is Heron Therapeutics quarterly total liabilities?
The current quarterly total liabilities of HRTX is $260.78 M
What is the all time high quarterly total liabilities for Heron Therapeutics?
Heron Therapeutics all-time high quarterly total liabilities is $265.70 M
What is Heron Therapeutics quarterly total liabilities year-on-year change?
Over the past year, HRTX quarterly total liabilities has changed by +$3.80 M (+1.48%)